Determination of the Relationship of Serum Hyaluronic Acid Levels to the Degree of Liver Fibrosis in Biopsies of Patients with Chronic Viral Hepatitis B and C by Moghaddam, Faride Moradi et al.
Hepat Mon 2010; 10(3): 168-172
ORIGINAL
 A RTICLE
Determination of the Relationship of Serum Hyaluronic Acid Levels to 
the Degree of Liver Fibrosis in Biopsies of Patients with Chronic Viral 
Hepatitis B & C
Faride Moradi Moghaddam 1, Hossein Arrbabi 1*, Mohammad Khajedaloei 2
1 Department of Internal Medicine, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Public Medicine, Ghaem Hospital, Mashad University of Medical Sciences, Mashhad, Iran
Introduction
C
hronic injury to the liver leads to its fibrosis (1). 
Hepatitis  B  and  C  are  examples  of  viral 
infections  that  cause  chronic  hepatitis;  even 
asymptomatic  patients  show  some  degree  of  liver 
fibrosis (LF) that can range from mild to end-stage 
cirrhosis  (2-4).  Determining  the  degree  of  LF  in 
chronic viral hepatitis is necessary in determining 
a  patient’s  prognosis  and  indications  for  therapy. 
Although liver biopsy is a gold- standard procedure 
in determining the stage and grade of LF (3, 5-7), it can 
be associated with complications (e.g. bleeding and 
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Background and Aims: Determining the stage of liver fibrosis and the grade of necroinflammation is important in predicting 
the prognosis and treatment response of patients with chronic viral hepatitis. Liver biopsy is associated with several technical 
problems and complications; therefore, its repetitive performance as a procedure in evaluating treatment response and in 
following up patients is not recommended. This study was performed to determine the correlation of serum hyaluronic acid 
(HA) levels with the stage and grade of histopathologic liver changes in patients with chronic hepatitis B and C.
Methods: This analytical cross-sectional study was performed on 69 patients with chronic hepatitis B or C in Mashhad, 
Iran, who were referred to our clinic and underwent liver biopsy and blood sampling simultaneously in 2006-2007. None 
of the patients were on medication that would affect the serum levels of (HA) and patients with signs of arthropathy were 
excluded from the study.
Results: Out of the 69 patients in this study, 48 (69.6%) were male and 21 (30.4%) were female. The causative virus in 
29 patients (42%) was hepatitis C and in the rest (n = 40, 58%) hepatitis B. The severity of liver fibrosis (stage) had a 
direct correlation (r = 0.25, P = 0.042) with the levels of (HA) and an inverse correlation with the platelet level (r = 0.37, 
P = 0.002). The degree of liver necroinflammation (grade) did not have a significant correlation with the levels of (HA) 
and alanine transaminase (r = -0.01, P = 0.9; r = 0.21, P = 0.09 respectively); instead, there was an inverse correlation 
with platelet levels (r = 0.36, P = 0.003).
Conclusions: Our study results correspond with those of other international studies; thus suggesting that the (HA) serum 
level is a useful marker in determining the severity of fibrosis in patients with chronic viral hepatitis. To form a definite 
conclusion, further studies on large groups should be performed.
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pain at the biopsy site, and a prolonged hospital stay), 
high hospital expenses (3, 8), false sample recording 
(9-11), and in some cases contraindications during the 
procedure, and dependence on pathologists’ skills in 
examining samples. Considering the aggressiveness 
of the procedure, repeating it for further evaluation 
and follow-up to determine treatment response is 
not recommended (6, 8). From a clinical perspective, 
the use of a non-invasive procedure in diagnosing 
and determining the presence and degree of LF, and 
as a tool in following up on the effects of anti-viral and 
antifibrotic medicines on the liver (8, 12, 13) is needed. 
LF is a complex and dynamic process with an increased 
extracellular matrix, increased activity of the matrix-
producing cells, release of cytokines and, ultimately, 
structural tissue changes (3). Hyaluronic acid (HA) is 
a polysaccharide with a high molecular weight found 
in the extracellular spaces. Through the bloodstream, 
it  enters  the  lymphatic  system  where  it  is  quickly 
degraded and removed by the sinusoidal endothelial 
cells (3, 14). Recent studies have shown that HA levels 
are elevated in patients with LF  (1-4, 6, 14-16). This 
study aimed to compare HA serum levels in different 
stages and grades (semi-quantitatively) in liver biopsies 
of patients with chronic hepatitis B and C.
Materials and Methods
This  analytical  cross-sectional  study  was  done 
on patients with chronic hepatitis B or C, who were 
referred  to  the  Gastrointestinal  and  Liver  Disease 
Research Center of Imam Reza Hospital in Mashhad 
from  2006  to  2007.  All  of  the  patients  involved 
in the study were selected from a census of their 
medical files, and a liver biopsy and a blood sample 
were concurrently done.
Those patients who did not have a liver biopsy 
done  concurrently  with  a  blood  test  were  not 
enrolled in the study. The population under study 
included  40  patients  with  chronic  hepatitis  B, 
and 29 patients with chronic hepatitis C, all with 
available serum samples. None of the patients used 
medicine that affected HA levels, at the time of the 
study. Considering that HA synthesis also occurs in 
the synovial membranes and that there is increased 
joint inflammation in these patients, those with signs 
of clinical arthropathy were excluded from the study. 
Also, those with a history of daily use of vitamin A 
and/or  amiodarone  and  methotrexate  causing  LF 
were excluded from the study. 
The HA test kit was provided by Corgenix Inc. 
(Colorado, USA, under license of Chugai Diagnostic 
Science Co.), and the HA serum levels were measured 
quantitatively by the enzyme-linked immunosorbent 
assay  (ELISA)  according  to  the  manufacturer’s 
instructions (normal value = 0-75 µg/l). The results 
were then compared with the findings from the liver 
biopsies. 
All liver biopsies were studied by histopathologic 
methods, using a trichromic stain that showed fibrosis. 
The degree of LF was determined based on Knodell’s 
scoring  system.  Slides  were  studied  by  experienced 
pathologists and findings classified into three groups, 
mild (stages 0,1,2), moderate (stages 3,4) and severe 
(stages 5,6). The degree of liver tissue inflammation and 
necrosis was also determined and classified according to 
Knodell’s scoring system, mild (grades 0-4), moderate 
(grades 5-8), relatively severe (grades 9-12) and severe 
(grades 13-18). None of the pathologists were aware of 
the patients’ serum HA levels. 
Data analysis was done with the software program 
SPSS version 13. First, the demographic findings, 
distributive and central indices of the patients were 
analyzed by the descriptive statistical method and 
appropriate charts were used. Chi-square tests were 
used to compare qualitative variables, and the t-test 
was used for quantitative variables. Non-parametric 
tests  were  used  for  non-Gaussian  distributive 
patterns. 
Patients’ blood sample results were retrieved from 
the archives of the blood bank of the Liver Research 
Center of the University of Mashhad. Patients were 
provided with information about the research and 
their consent obtained before the procedures were 
carried out. Patients’ details were kept confidential 
by the researchers.
Results
Out of the 69 patients studied, 48 (69.6%) were 
men and 21 (30.4%) women. The mean age of the 
patients was 34 ± 10. The youngest patient was 15 
years  old  and  the  oldest  61.  Twenty-nine  (42%) 
patients had chronic hepatitis C, while the rest (40 = 
58%) had chronic hepatitis B. The demographic and 
paraclinical findings of these patients, based on the 
viral agent for their chronic disease, are shown in Table 
1. There was no significant difference in the mean age, 
number of platelets, alanine transaminase (ALT) and 
HA levels between the two groups (chronic hepatitis 
B and C). The mean levels of HA, ALT and number 
of platelets were 54.48±25.34 µg/l, 87.91 ±71.4 µg/l 
and 175.92 ± 49.9×103/ml respectively. The mean of 
these variables based on the degree of LF (stage) and 
degree of liver necroinflammation (grade) is shown 
in Table 2 and 3. Spearman’s statistical test showed 
a significant, direct correlation between the severity 
of liver fibrosis (stage) and the level of HA (r = 0.25, 
P = 0.042) and a significant inverse correlation with Hepatitis Monthly, Summer 2010; 10(3): 168-172
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fibroblasts and other cells, especially the connective 
tissue and synovial membrane. A small percentage of 
HA is locally metabolized while the greater part of it 
enters the blood through the lymphatic system and 
from there goes into the liver where it is immediately 
metabolized by the hepatoendothelial cells (17, 18). 
In a healthy individual, HA spends half of its life in 
the blood stream (2-5 minutes). Its normal serum 
concentration is age-dependent. From the neonatal 
stage  to  puberty  and  then  during  adulthood,  its 
concentration  usually  rises.  Any  condition  that 
interferes with the removal of HA from the blood 
into the endothelial cells of the liver will cause its 
level to become elevated.
In this study, the relationship between serum HA 
levels and the degree of LF in patients with hepatitis 
B and C was determined. Our findings have shown 
similarities to those of previous studies done on this 
topic. Nyberg et al. (21) have shown that HA levels 
are  a  sensitive  tool  that  can  be  used  to  determine 
the degree of progressive liver injury in patients with 
primary biliary cirrhosis. Another study by Fried (18) 
showed that patients who developed LF from chronic 
veno-occlusive  diseases  also  presented  with  elevated 
HA  levels.  Other  similar  studies  involving  patients 
with  hepatitis  C  also  showed  a  direct  correlation 
between  fibrosis  in  liver  biopsies  and  elevated  HA 
levels, which completely corresponds to the findings 
of our recent study (7, 9, 10, 19). Our results were also 
similar to the studies of Wong and Skirpenova (9, 19), 
where no significant correlation between the degree 
of  inflammation  and  HA  and  serum  ALT  levels 
was found. Although this study showed an inverse 
correlation between the severity of fibrosis and the 
number of platelets, this had never been studied before 
in prior research. Wyatt et al. had studied children with 
fibrocystic diseases and discovered that patients who 
developed LF had a reasonable elevation in serum HA 
levels, compared to those who did not have fibrosis 
(17). Some other researchers have found similar results 
in their studies of chronic liver disease in both children 
and adults (5, 16). In Iran, Montazeri et al., (2005) also 
reported a relationship between serum hyaluronate and 
the severity of inflammation and fibrosis in patients 
with non-HBeAg hepatitis B (6).
Conclusions
The correlation of the results in our study with 
similar  studies  worldwide  proves  the  theory  that 
measuring serum levels of HA is a useful tool in 
determining the severity of fibrosis in patients with 
hepatitis  B  and  C  and  is  a  suitable  non-invasive 
procedure  that  can  replace  invasive  liver  biopsy. 
Nevertheless,  further  studies  on  a  large  group  of 
patients  should  be  performed  before  reaching  a 
definite conclusion.
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